No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 9 | 18 | 28 | 36 | 31 | 29 | N/A | N/A |
| Operating profit | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | $m | -41 | -72 | -133 | -232 | -112 | -26 | N/A | N/A |
| EPS reported | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | Locked | Locked | Locked |
| Environmental score | Locked | Locked | Locked |
| Social score | Locked | Locked | Locked |
| Governance score | Locked | Locked | Locked |
| Risk rating | Locked | Locked | Locked |
Company overview
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.